David Shima

Sequential SNARE disassembly and GATE-16-GOS-28 complex assembly mediated by distinct NSF activities drives Golgi membrane fusion.

VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts.

Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis.

Mutations in dynein link motor neuron degeneration to defects in retrograde transport.

VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system.

Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve.

The role of vascular endothelial growth factor in ocular health and disease.

VEGF function in vascular pathogenesis.

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.

Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).

An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis.

Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization.

Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.

Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration.

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Molecular mapping and functional characterization of the VEGF164 heparin-binding domain.

RGS5 expression is a quantitative measure of pericyte coverage of blood vessels.

Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

Delta-like 4 is indispensable in thymic environment specific for T cell development.

The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study.

Delivery of anti-angiogenic molecular therapies for retinal disease.

Forkhead box N4 (Foxn4) activates Dll4-Notch signaling to suppress photoreceptor cell fates of early retinal progenitors.

Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale.

Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.

VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.

A2E induces IL-1ß production in retinal pigment epithelial cells via the NLRP3 inflammasome.

Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.

Differential apicobasal VEGF signaling at vascular blood-neural barriers.